Agi-bromhexine Agimexpharm medicine helps to dilute phlegm in acute and chronic bronchial diseases (30ml)

Dosage form Oral solution
Specifications Box of 1 bottle x 30ml
Ingredient Bromhexin hydrochloride
Indication Chronic respiratory infections, pulmonary dust, acute bronchitis, bronchiectasis, chronic obstructive pulmonary, chronic bronchitis, respiratory infections
Contraindication Drug allergy

Ingredient

Thành phần cho 5ml

Composition information	Content
Bromhexin hydrochloride	4mg

Uses

indications

Agi-bromhexine drugs help dilute phlegm in acute and chronic bronchial diseases accompanied by abnormal mucus secretion and weakened mucus.

Pharmacology

Pharmacological group: Respiratory system - Mucus thinner

ATC code: R05cb02

Bromhexin is a synthetic derivative from the active ingredient Vasicin.

Clinically, bromhexin is noticed that increases the ratio of bronchodilatoma.

Bromhexin increases the transportation of mucus by reducing the slightness of mucus and active epithelial activity with cylindrical velvet (expuled with mucus).

In clinical trials, bromhexin shows the effect of diluting the secretion and transporting secretions in the bronchial sugar to facilitate the sputum and cough.

After treatment with bromhexin, antibiotic concentration (amoxicilin, erythromycin, oxytetracyclin) in phlegm and bronchial -lung secretion increases.

pharmacokinetics

absorption:

Bromhexin is absorbed quickly and completely through the gastrointestinal tract.

Birth is equivalent after taking solid form and solution.

Absolute bioavailability of hydrochloride Bromhexin is about 22.2 ± 8.5% and 26.8 ± 13.1% corresponding to AGI-Bromhexine tablet and solution.

The first amount of metabolites is about 75 - 80%.

Use the same food leads to increased bromhexin levels in plasma.

Distribution:

After using intravenous lines, bromhexin is distributed quickly and widely throughout the body with average distribution (VSS) up to 1209 ± 206 l (19 l/kg). Has studied the distribution into the lung tissue (bronchial and parenchyma) after taking 32 mg and 64 mg of bromhexin. The concentration of the lung tissue after 2 hours of drug use, the concentration at the bronchial-lucranial tissue is 1.5-4.5 times higher and the lung parenchyma is about 2.4-5.9 times higher than the plasma concentration.

Bromhexin binding in a constant form with plasma proteins is about 95% (unlimited link).

Metabolism:

Bromhexin metabolizes almost completely into diverse hydroxy metabolites and into dibromanthanilic acid. All pass chemicals and bromhexin themselves are combined in the form of n-glucuronid and o-glucuronid. There is no significant evidence of changing the metabolic method due to sulphonamid, oxytetracycline or erythromycin. Therefore, the corresponding interaction is due to the CYP 450 2C9 and 3A4 substrate.

Era:

After using intravenous tract, bromhexin has a high rate of extraction within the range of blood flow through the liver, 843 - 1073 ml/minute leads to a large difference between individuals and on the same individual (CV> 30%). After using bromhexin with radioactive marking, about 97.4% ± 1.9% of the dose found in the form of radioactive in the urine, with the original active ingredient below 1%. Plasma bromhexin concentration decreases with exponential expansion. After taking single -dose from 8 to 32 mg, the last half -life is in the range of 6.6 - 31.4 hours. Half -life relevant lifetime to predict multi -dose pharmacokinetics is about 1 hour, so there is no accumulation after multi -dose use (accumulation coefficient 1.1).

General

Bromhexin represents the pharmacokinetics proportional to the dose within 8 to 32 mg after oral use.

There is no bromhexin pharmacokinetic data in high patients or patients with liver or kidney failure. Clinical experience does not show problems related to safety on these subjects.

There are no studies on interactive with oral anticoagulants or digoxin. The pharmacokinetics of bromhexin are not affected relevant when using ampicillin or oxytetracyclin simultaneously. The previous comparison did not see the corresponding interaction between bromhexin and erythromycin.

There is no related interaction report for a long time for drug circulation to suggest negligible interaction with these drugs.

Before taking Agi-bromhexine Agimexpharm medicine helps to dilute phlegm in acute and chronic bronchial diseases (30ml)

How to use

Agi-bromhexine drugs for oral use.

Dosage

Adults and children over 12 years: Taking dose of 10 ml (8 mg) 3 times daily

Children 6 - 12 years old: take a dose of 5 ml (4 mg) 3 times daily

Children 2 - 6 years old: Topes of 2.5 ml (2 mg) 3 times daily

Children under 2 years of age: dose of 1.25 ml (1 mg) 3 times daily

At the beginning of treatment, it is necessary to increase the total daily dose to 48 mg (60 ml or 20 ml 3 times daily) in adults and children over 12 years old.

The dose cup includes in the product with the appropriate dose line.

Sugary syrup is therefore suitable for patients with diabetes and children.

It is necessary to notify patients treated with Agi-Bromhexine for the ability to increase the amount of secretion.

In the indication of acute respiratory disease, based on each patient to decide whether the doctor's opinion depends on the symptoms that improve or worsen during treatment.

Agi -bromhexine treatment time does not exceed 8 - 10 days without consulting your doctor.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Based on the overdose reports by accident and/or using the wrong drug, the observation symptoms are suitable for the side effects at the recommended dose and may need symptom treatment.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Agi-Bromhexine drugs often experience unwanted effects (ADR) such as:

immune system disorders

Rare (≥ 1/10,000 to Unknown (not estimated from available data): bronchospasm.

Not common (1/1,000 to Rare (≥ 1/10,000 to

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

contraindicated

Agi-bromhexine drugs contraindicated in the following cases:

Hypersensitivity to Bromhexin hydrochloride and the ingredients in the drug.

Caution when using

There are very few serious skin damage reports such as Stevens -Johnson syndrome and poisoned epidermal epidermal necrosis (toxic Epidermal Necrolysis -Ten temporarily related to the use of phlegm as bromhexin. Most cases are explained by the disease that the patient is suffering from and/or medication. Moreover, in the early stages of Stevens-Johnson or Ten's syndrome, the patient first has a million-like influenza-like influenza like fever, human aches, rhinitis, cough and sore throat. Due to being mistaken by these unchanged influenza varieties, people can start treating symptoms of cough and colds. Therefore, if a few new lesions appear on the skin or mucosa, you should see a doctor immediately and stop treatment with bromhexin.

In each ml of the drug contains 0.49 g of sorbitol. Sorbitol can cause unpleasant digestive symptoms and for mild laxative effect.

Do not use drugs in patients with rare genetic diseases with fructose. The drug may have a mild laxative effect.

Be careful when using AGI-Bromhexine simultaneously and cough inhibitors to avoid accumulating secretions due to cough decline and this combination should only be used after evaluation of benefits-risks.

Use cautiously in patients with stomach ulcers.

Use cautiously in asthma patients because bromhexin can cause bronchospasm in some sensitive people.

Must be very careful when using AGI-Bromhexine in patients with severe renal impairment or liver failure.

In patients with severe renal impairment, accumulating the metabolites of bromhexin formed in the liver may occur.

Caution used in patients is elderly, weak or too weak without sputum.

The effect of the drug on the ability to drive and operate machinery

has not seen the drug that affects the ability to drive and operate machinery.

Use drugs for women during pregnancy and lactation

Women during pregnancy:

Data using bromhexin for pregnant women is limited.

Animal studies do not show direct or indirect harmful effects related to reproductive toxicity.

Women who are likely to be pregnant or are using contraception should consult a doctor carefully before taking this medication.

Women during breastfeeding:

It is unclear whether bromhexin/chemical substances will be secreted into the mother's milk.

Data available for pharmacological/animal toxicity shows the excretion of bromhexin/substances for breast milk.

cannot rule out the risk for breastfeeding.

Do not use Agi-bromhexine during breastfeeding.

reproductive ability:

has not conducted research on the effects of AGI-bromhexine on human fertility.

Based on preclinical experience, there is no sign that bromhexin has a fertility.

Drug interaction

has not seen a report on adverse interactions with other clinical drugs.

Avoid using bromhexin with drugs that reduce secretion like atropine -style drugs.

Using bromhexin combination with antibiotics increases antibiotic concentration into lung and bronchial tissue; Therefore, the drug is used in combination with antibiotics in the treatment of respiratory tract infections.

To avoid interactions between drugs, notify the doctor or pharmacist about the drugs being used.

Cavalry of the drug: Due to no studies on the correspondence of the drug, not mixing this drug with other drugs.

Storage

Leave a cool place, avoid light, temperatures below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.